ID
ACHN

Integral Derivatives’s Achillion Pharmaceuticals ACHN Stock Holding History

Integral Derivatives’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,368
Closed -$44K – 1140
2017
Q4 		$44K Buy
+15,368
New +$55.8K ﹤0.01% 1073
2017
Q1 		– Sell
-13,754
Closed -$57K – 1453
2016
Q4 		$57K Buy
+13,754
New +$73.1K ﹤0.01% 1082
2014
Q4 		– Sell
-10,116
Closed -$124K – 1614
2014
Q3 		$101K Sell
10,116
-5,501
-35% -$51.1K ﹤0.01% 1333
2014
Q2 		$118K Sell
15,617
-1,103
-7% -$4.4K ﹤0.01% 1258
2014
Q1 		$55K Sell
16,720
-13,950
-45% -$48.8K ﹤0.01% 1253
2013
Q4 		$102K Buy
+30,670
New +$89K ﹤0.01% 1411

Other funds holding ACHN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Integral Derivatives's ACHN Position: Q1 2018 in Review

Integral Derivatives sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 15,368 shares — an estimated $44K sold.

Integral Derivatives first reported a position in ACHN in Q4 2013 and held it in 6 quarters. The position peaked at $118K in Q2 2014. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Integral Derivatives reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Integral Derivatives sold 15,368 Achillion Pharmaceuticals shares in Q1 2018, an estimated $44K.
  • Integral Derivatives first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Integral Derivatives's Achillion Pharmaceuticals position peaked at $118K in Q2 2014.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.